Drugs / DP-R213
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03010267 | Jan → Mar 2017 | — | Alvogen Korea | Completed | Met primary |
| Phase 1 | NCT02762643 | May → Jul 2016 | — | Alvogen Korea | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DP-R213 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03010267 ↗ |